Preferences help
enabled [disable] Abstract
Number of results
2018 | 23 | 3 | 124-127
Article title

Miejsce swoistej immunoterapii alergenowej w alergicznych chorobach oczu

Title variants
Placement of allergen specific immunotherapy in ocular allergy
Languages of publication
Zachorowalność na alergiczne choroby oczu rośnie na świecie wraz ze wzrostem innych chorób alergicznych, szczególnie z alergicznym nieżytem nosa. Niestety badania nad epidemiologią i immunoterapią w alergii oczu są nadal nieliczne w porównaniu z badaniami dotyczą- cymi wszystkich aspektów alergicznego nieżytu nosa. Autor przedstawia 3 prace ze swoistej immunoterapii alergenowej dotyczące alergii oczu i omawia niektóre, z licznych badań, dotyczących immunoterapii nieżytu alergicznego nosa i spojówek, które oceniały osobno poprawę objawów ocznych. Artykuł próbuje wykazać zasadność dalszych badań nad właściwym miejscem w alergologii wiedzy o alergii oczu, a w szczególności ustalenia wskazań do swoistej immunoterapii w alergicznych zapaleniach spojówek.
Morbidity of ocular allergic diseases has been growing all over the world alongside with other allergic diseases, especially the allergic rhinitis. Unfortunately epidemiologic data and studies about immunotherapy in ocular allergy have so far been scarce in comparison to extensive research of various aspects of allergic rhinitis. The author presents three studies of allergen-specific immunotherapy in ocular allergy and certain of numerous studies on allergic conjunctivitis (AC) and allergic rhinoconjunctivitis (ARC) that included separate evaluation of ocular symptoms. This article emphasizes the need for further research on the proper placement of ocular allergies in allergology and establishing indications for allergen-specific immunotherapy of allergic conjunctivitis
Physical description
  • DOBROSTAN, Ośrodek Badań Klinicznych, Wrocław
  • 1. Del Prete A. A history of allergic oculorhinoconjunctivitis. Allergy 2002; 57(suppl 73), abstr. 1152.
  • 2. Novaes P, Nascimento S, Kara-Jose N, et al. Ambient levels of air pollution induce globlet-cell hyperplasia in human conjunctival epithelium. Environ Health Perspect 2007; 115: 1753-6.
  • 3. Rummenie VT, Matsumoto Y, Drogu M, et al. Tear cytokine and ocular sulface aberrations following brief passive cigarette smoke exposure. Cytokine 2008; 43: 200-8.
  • 4. Mantelli F, Lambiase A, Bonini S, Bonini S. Clinical trials in allergic conjunctivitis: a systematic review. Allergy 2011; 66: 919-24.
  • 5. Bogacka E. Immunoterapia alergicznych chorób oczu. Alergologia Współczesna, 2003.
  • 6. Drachenberg KJ, et al. Short-course specific Immunotherapy (SIT) adjuvanted by Monophosphoryl Lipid A (MPL). A multi-centre, double-blind, placebo-controlled study. Poster 103, Posters of Allergy Therapeutics of XIX Congress EAAACI, Lisbon, 2000.
  • 7. Drachenberg KJ, et al. Three-year short-term Specific Immunotherapy (SIT). A multi-centre, double-blind, placebo-controlled study with L-Tyrosine-adsorbed Pollen Allergoids. Poster 107, Posters of Allergy Therapeutics of XIX Congress EAAACI, Lisbon, 2000.
  • 8. Papageorgiou-Saxoni F. Double blind placebo-controlled evaluation of sublingual immunotherapy with standardized olive tree pollen extract in patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1977; 37(57 suppl): 161.
  • 9. ARIA Workshop Report. J Allergy Clin Immunol 2001; 108: 153-61.
  • 10. Kari O. Tear fluid ECP and specific immunotherapy. All Clin Immunol Int 1997; suppl 4, poster 127.
  • 11. Arsovski Z. The effect of specific immunotherapy (SIT) on grass pollen - induced rhinoconjunctivitis. Allergy 2002; 57(suppl 73), abstr. 131.
  • 12. Schlinzig EM. Short-term immunotherapy with a tyrosine-adsorbed pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) in the practice of an allergologist. Posters of Allergy Therapeutics, XXI Congress of the EAACI, Naples, 2002: 16-17.
  • 13. Danek K. Effectiveness evaluation of the specific immunotherapy in seasonal allergic conjunctivitis. Allergy 2002; 57(suppl 73), abstr. 738.
  • 14. Fauquert JL. Allergy in vernal kerato-conjunctivitis in children. All Clin Immunol Int 1997; suppl 4, poster 137.
  • 15. WHO Position Paper: Allergen immunotherapy. Allergy 1998; 44: 13-14.
  • 16. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018; 73: 765- 98.
  • 17. Muraro A, Roberts G, Halken S, et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018; 73: 744-64.
  • 18. Canonica W. Sub-lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64: 1-59.
  • 19. Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy 2011; 41: 1263-72.
  • 20. Frølund L, Durham SR, Calderon M, et al. Sustained effect of SQ- -standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010; 65: 753-7.
  • 21. Mussler S, Thum-Ottmer S, Meyer H, Narkus A. Influence of high- -dose grass pollen sublingual immunotherapy on allergic eye and nose symptoms. Allergy 2010; suppl 92: 73-4.
  • 22. Fiocchi A, Fox AT. Preventing progression of allergic rhinitis: the role of specific immunotherapy. Arch Dis Child Educ Prac Ed 2011; 96: 91-100.
  • 23. Nelson HS, Nolte H, Creticos P, Maloney J. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. Allergy Clin Immunol 2011; 127: 72-80.
  • 24. Maloney J, Bernstein DI, Nelson H, Creticos P. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014; 112: 146-53.
  • 25. Tworek A, Bocheńska-Marciniak M, Kupryś-Lipińska I, et al. Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis. Am J Rhinol Allergy 2013; 27: 304-8.
  • 26. Didier A, Mailing HJ, Worm M, et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation as measured by a recommended daily combined score. Clin Transl Allergy 2015; 5: 12.
  • 27. Matsuoka T, Bernstein DI, Masuyama K, et al. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. Pediatr Allergy Immunol 2017; 28: 661-7.
  • 28. Leonardi A, Bogacka E, Fauquert JL, et al. Ocular Allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Position paper. Allergy 2012; 67: 11.
  • 29. Rondon C, Blanca-Lopez N, Campo P, et al. Specific immunotherapy in local allergic rhinitis.AS randomised double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy 2018; 73: 905-15.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.